PRESS RELEASE published on 01/15/2025 at 07:30, 4 months 15 days ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
PRESS RELEASE published on 01/15/2025 at 07:30, 4 months 15 days ago Informations privilégiées / Autres communiqués GenSight Biologics annonce les résultats cliniques à 5 ans de la thérapie génique LUMEVOQ chez les patients atteints de NOHL, démontrant une amélioration bilatérale de l'acuité visuelle et un profil de sécurité favorable Thérapie Génique GenSight Biologics NOHL LUMEVOQ Résultats Cliniques
BRIEF published on 01/13/2025 at 11:31, 4 months 17 days ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
BRIEF published on 01/13/2025 at 11:31, 4 months 17 days ago Heights Capital Management dépasse 5% du capital de GenSight Biologics Augmentation De Capital GenSight Biologics Actions Et Droits De Vote Heights Capital Management Participation Capital
PRESS RELEASE published on 01/13/2025 at 11:26, 4 months 17 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management, Inc. pour Gensight Biologics S.A. avec détention de 7 574 746 actions et 9,62% des droits de vote Déclaration Actions Franchissement De Seuils Gensight Biologics S.A. Heights Capital Management Inc.
BRIEF published on 12/24/2024 at 20:51, 5 months 6 days ago GenSight Biologics obtient un financement de 1,5 million d'euros auprès d'investisseurs existants Financement Investisseurs Thérapie Génique Mandats GenSight Biologics
BRIEF published on 12/24/2024 at 20:51, 5 months 6 days ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 5 months 6 days ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
PRESS RELEASE published on 12/24/2024 at 20:46, 5 months 6 days ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 1,5 million d'euros auprès d'investisseurs existants pour le développement de thérapies géniques innovantes. Perspectives de croissance et objectifs à court terme Croissance Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 11/13/2024 at 07:35, 6 months 17 days ago GenSight Biologics dépose le dossier LUMEVOQ® auprès de l'ANSM Thérapie Génique GenSight Biologics Programme D'accès Anticipé Neuropathie Optique Héréditaire De Leber Soumission Réglementaire
Published on 05/31/2025 at 03:30, 2 hours 44 minutes ago Avant Brands Inc. Announces Voting Results From 2025 Annual General Meeting of Shareholders
Published on 05/31/2025 at 01:45, 4 hours 29 minutes ago GLG Life Tech Corporation Reports 2025 First Quarter Financial Results
Published on 05/30/2025 at 23:10, 7 hours 4 minutes ago CORRECTION: Nextech3D.ai Migrates MAP Dynamics to AWS, Enabling Scalable AI Architecture and Accelerated Deployment
Published on 05/30/2025 at 23:00, 7 hours 14 minutes ago Battery X Metals Achieves Full Capacity Recovery on a Real-World Imbalanced Battery from the #2 Out-of-Warranty Electric Vehicle Model in the United States in Preliminary Trial
Published on 05/30/2025 at 22:30, 7 hours 44 minutes ago Pinetree Capital Ltd Announces Election of Directors
Published on 05/30/2025 at 21:22, 8 hours 51 minutes ago CPI PROPERTY GROUP publishes financial results for the first quarter of 2025
Published on 05/30/2025 at 20:30, 9 hours 44 minutes ago IUTE GROUP ISSUES EUR 140 MILLION NEW SENIOR SECURED EUR 2025/2030 BONDS – Strong demand from existing investors and new subscriptions
Published on 05/30/2025 at 18:05, 12 hours 9 minutes ago Eurobattery Minerals will submit additional documentation for the EPA at the end of June
Published on 05/30/2025 at 18:04, 12 hours 10 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 05/30/2025 at 18:00, 12 hours 14 minutes ago XTransfer participera pour la première fois en tant que sponsor 4 étoiles au salon Money20/20 Europe 2025
Published on 05/30/2025 at 22:00, 8 hours 14 minutes ago Information on the Annual Financial Statements
Published on 05/30/2025 at 18:14, 11 hours 59 minutes ago Emova Group - Rapport annuel de Durabilité 23/24
Published on 05/28/2025 at 23:00, 2 days 7 hours ago Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 2 days 7 hours ago Engagements collectifs de conservation de titres de la société
